Full-Time

Principal Instrument Replacement Lead

Lifecycle Program

Updated on 8/1/2026

Deadline 4/30/27
Waters Corporation

Waters Corporation

10,001+ employees

Analytical instruments, software, and services provider

No salary listed

Milpitas, CA, USA + 2 more

More locations: New Castle, DE, USA | Milford, MA, USA

Hybrid

Hybrid work is indicated; the posting lists locations in Massachusetts, California, and Delaware.

Category
Business & Strategy (1)
Required Skills
CRM
Salesforce
Data Analysis

Get referred to Waters Corporation

See people who can refer or advise you

Requirements
  • A bachelor's degree in business, engineering, economics, or a related field.
  • At least 12 years of experience in lifecycle management, commercial excellence, sales operations, service operations, or enterprise transformation.
  • Experience leading complex, cross-functional programs in a global, multi-business-unit environment.
  • Strong understanding of installed base management and asset lifecycle concepts.
  • Strong understanding of commercial motions supporting replacement, upgrades, and renewals.
  • Strong understanding of sales and service operating models.
  • Experience working with customer relationship management, installed base, and analytics platforms such as Salesforce or similar systems.
  • Ability to influence without authority and drive alignment across senior stakeholders.
  • Strong analytical ability to translate strategy into execution.
  • Results-oriented approach with ownership and urgency.
Responsibilities
  • Collaborate with commercial leadership and functional subject-matter experts to define an enterprise instrument replacement strategy across regions, product lines, and customer segments.
  • Lead gap analysis and develop a future-state model for replacement timing logic, segmentation, and prioritization frameworks based on installed base health, service signals, technology evolution, and customer value.
  • Facilitate cross-functional working sessions to define principles for repair versus replacement, upgrade pathways, and trade-in or migration models.
  • Collaborate with commercial leadership and functional subject-matter experts to design and govern future-state replacement operating models.
  • Define installed base intelligence and lifecycle triggers, commercial plays and go-to-market motions, and pricing guidance.
  • Ensure replacement programs are simple to understand, easy to deploy, and measurable for adoption by business units.
  • Lead cross-functional collaboration across Sales, Service, Commercial Excellence, Product Management, Finance, Information Technology, and Analytics.
  • Facilitate executive alignment and decision-making by articulating trade-offs, value cases, and risks.
  • Define success metrics and key performance indicators, and support governance and the operating cadence for instrument replacement excellence.
  • Partner with stakeholders to ensure accurate and actionable installed base visibility.
  • Embed lifecycle and replacement triggers into customer relationship management and analytics platforms.
  • Enable consistent tracking of replacement opportunities, conversion, and value realization.
  • Define and track enterprise-level impact on revenue retention and growth, margin and asset productivity, and customer experience and loyalty.
  • Identify systemic bottlenecks and improvement opportunities and partner with business units to address them.
  • Scale best practices globally while enabling regional and segment-specific execution flexibility.
Desired Qualifications
  • Lean or continuous improvement experience.

Waters Corporation provides analytical system solutions, software, and services for scientists across biopharma, clinical research, forensics, life science research, food and beverage, and environmental sectors. Its products include high-performance analytical instruments like the BioAccord System, paired with software and ongoing support to enable precise, reproducible results. The company operates by selling instruments and software and offering maintenance and services to enhance user experience and reliability. Compared to competitors, Waters offers an integrated package of hardware, software, and service across multiple markets, focused on delivering accurate analyses and end-to-end workflow solutions rather than just standalone devices. Its goal is to unlock the potential of science by solving problems that affect human health and well-being.

Company Size

10,001+

Company Stage

IPO

Headquarters

Milford, Connecticut

Founded

1958

Get referred to Waters Corporation

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Biopharma spending supports instrument refreshes and consumables pull-through.
  • Clinical diagnostics applications expand with earlier disease detection demand.
  • Food, water, and environmental testing create diversified compliance-driven growth.

What critics are saying

  • Thermo Fisher, Danaher, and Agilent pressure pricing and platform share.
  • Chinese vendors undercut Waters in cost-sensitive public labs and CROs.
  • Biopharma capital spending delays weaken system sales and consumables demand.

What makes Waters Corporation unique

  • Waters dominates regulated chromatography and mass spectrometry workflows.
  • Its portfolio combines instruments, informatics, consumables, and services.
  • Biopharma generated 58% of 2024 sales, anchoring recurring demand.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Hybrid Work Options

Growth & Insights and Company News

Headcount

6 month growth

16%

1 year growth

16%

2 year growth

14%
PR Newswire
Apr 14th, 2026
Waters launches omniDAWN MALS detector for UHPLC, enabling 4x faster analysis of large molecules

Waters Corporation has launched the omniDAWN Multi-Angle Light Scattering Photometer, the first extended-range MALS detector designed for ultra high performance liquid chromatography workflows. The device features 18 detection angles and delivers chromatographic run times up to four times faster than conventional methods. The photometer extends UPLC-compatible sizing tenfold, from approximately 50 to 500 nanometres in radius, enabling characterisation of complex molecules including protein aggregates, viral vectors and lipid nanoparticles. It achieves a 10-fold improvement in absolute molar mass measurements whilst reducing sample consumption by 30–50% and solvent use by roughly 40%. The device integrates with Waters UPLC systems and is powered by ASTRA software, supporting analysis across drug discovery, development and quality control. The omniDAWN photometer will be available globally in summer 2026.

PR Newswire
Apr 8th, 2026
Waters gains FDA clearance for at-home cervical cancer screening kit with HPV assay

Waters Corporation has received FDA clearance for the Onclarity HPV Self-Collection Kit and approval for the BD Onclarity HPV Assay with extended genotyping for at-home use. The kit enables cervical cancer screening from home, addressing barriers that prevent many individuals from routine testing. Approximately 60% of cervical cancer cases occur in unscreened or under-screened individuals. The BD Onclarity HPV Assay is the only FDA-approved test identifying six individual HPV genotypes and three pooled groups, making it the most comprehensive screening tool available in the US. The kit will be available by prescription in coming months and is covered by private insurance, Medicaid and Medicare. Waters is establishing partnerships for broader nationwide access, with patients able to collect samples at home and mail them to laboratories for processing.

Paul Hastings LLP
Mar 23rd, 2026
Waters Corporation subsidiary raises $3.5B through senior notes offering

Paul Hastings advised underwriters including Barclays Capital, Citigroup Global Markets and J.P. Morgan Securities in a $3.5 billion senior notes offering by Augusta SpinCo Corporation, a Waters Corporation subsidiary. The SEC-registered offering comprises five tranches of senior notes maturing between 2027 and 2036, with interest rates ranging from 4.321% to 5.245%. The notes are guaranteed by Waters and certain subsidiaries. Partner Jeff Ramsay led the Paul Hastings team, which included partners Morgan Bale, Ismael Duran and Daniel Nicholas, along with several associates.

Yahoo Finance
Mar 19th, 2026
Waters Corporation stock down 22.8% year-on-year, underperforming Dow's 11.2% rise

Waters Corporation (WAT), a leading scientific instruments manufacturer, is underperforming the Dow Jones Industrial Average significantly. The stock trades 28.8% below its 52-week high of $414.15 and has declined 22.3% year-to-date, compared to the Dow's 3.8% decline. The Milford, Massachusetts-based company, with a market cap of $28.9 billion, specialises in analytical technologies including liquid chromatography and mass spectrometry for pharmaceutical, life sciences and industrial applications. Despite reporting solid fourth-quarter results with revenue of $932 million, up 7% year-over-year, and adjusted earnings per share rising 10% to $4.53, investor sentiment has soured. Cautious first-quarter guidance and concerns over its acquisition of Becton Dickinson's biosciences unit, which is underperforming expectations, have weighed on the stock.

Yahoo Finance
Mar 17th, 2026
Waters Corporation Q4 results mixed as research tools sector faces 20.9% share price decline

Waters Corporation reported Q4 revenues of $932.4 million, down 45.4% year on year, meeting analysts' expectations. The analytical instruments manufacturer delivered mixed results, with next quarter's revenue guidance exceeding expectations but earnings per share guidance falling short. The research tools and consumables sector reported a satisfactory Q4 overall, with the 10 tracked stocks beating revenue consensus estimates by 1.2%. However, share prices have struggled, declining 20.9% on average since latest earnings results. Founded in 1958, Waters develops analytical instruments, software and consumables for liquid chromatography, mass spectrometry and thermal analysis. CEO Udit Batra highlighted the company achieved high single-digit revenue growth and double-digit adjusted EPS growth in 2025, with momentum expected to continue into 2026.